FY2024 EPS Estimates for Danaher Lowered by Zacks Research

Danaher Co. (NYSE:DHR - Free Report) - Stock analysts at Zacks Research cut their FY2024 EPS estimates for shares of Danaher in a report released on Tuesday, November 12th. Zacks Research analyst R. Department now anticipates that the conglomerate will post earnings of $7.49 per share for the year, down from their previous estimate of $7.56. The consensus estimate for Danaher's current full-year earnings is $7.51 per share. Zacks Research also issued estimates for Danaher's Q4 2024 earnings at $2.14 EPS, Q1 2025 earnings at $2.05 EPS, Q2 2025 earnings at $1.91 EPS, Q3 2025 earnings at $1.94 EPS, Q4 2025 earnings at $2.34 EPS, FY2025 earnings at $8.24 EPS, Q1 2026 earnings at $2.21 EPS, Q2 2026 earnings at $2.25 EPS and FY2026 earnings at $9.28 EPS.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating analysts' consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The company had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the previous year, the business earned $2.02 earnings per share. The company's quarterly revenue was up 3.1% on a year-over-year basis.

Several other research firms have also weighed in on DHR. KeyCorp upped their target price on shares of Danaher from $290.00 to $310.00 and gave the stock an "overweight" rating in a report on Wednesday, October 23rd. The Goldman Sachs Group upped their price objective on shares of Danaher from $225.00 to $250.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 24th. Wolfe Research upgraded shares of Danaher from a "peer perform" rating to an "outperform" rating and set a $285.00 target price for the company in a research note on Thursday, October 31st. StockNews.com upgraded Danaher from a "hold" rating to a "buy" rating in a research report on Wednesday, November 6th. Finally, Robert W. Baird cut their price objective on Danaher from $278.00 to $277.00 and set an "outperform" rating for the company in a research report on Wednesday, October 23rd. Five investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $287.16.

Danaher Price Performance

NYSE:DHR traded down $2.39 during trading hours on Thursday, reaching $239.14. The company had a trading volume of 1,260,017 shares, compared to its average volume of 2,739,077. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The stock has a 50-day moving average of $263.42 and a two-hundred day moving average of $260.64. Danaher has a one year low of $204.15 and a one year high of $281.70. The firm has a market capitalization of $172.72 billion, a PE ratio of 46.08, a PEG ratio of 4.40 and a beta of 0.85.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. The ex-dividend date of this dividend was Friday, September 27th. Danaher's dividend payout ratio is currently 20.61%.

Insider Activity

In related news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares of the company's stock, valued at approximately $1,130,374.44. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 11.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of DHR. Vanguard Group Inc. increased its stake in Danaher by 7.4% in the 1st quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate's stock valued at $15,009,928,000 after buying an additional 4,163,657 shares during the last quarter. FMR LLC grew its holdings in shares of Danaher by 15.8% in the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate's stock valued at $6,566,116,000 after acquiring an additional 3,217,631 shares in the last quarter. Legal & General Group Plc increased its position in shares of Danaher by 2.4% in the second quarter. Legal & General Group Plc now owns 5,964,031 shares of the conglomerate's stock valued at $1,490,112,000 after acquiring an additional 139,989 shares during the last quarter. Capital Research Global Investors raised its holdings in Danaher by 1.0% during the first quarter. Capital Research Global Investors now owns 5,125,470 shares of the conglomerate's stock worth $1,279,932,000 after acquiring an additional 52,679 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Danaher by 3.0% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate's stock valued at $1,417,342,000 after purchasing an additional 148,251 shares during the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.